Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Oct;71(10):7198–7206. doi: 10.1128/jvi.71.10.7198-7206.1997

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

J R Mascola 1, M K Louder 1, T C VanCott 1, C V Sapan 1, J S Lambert 1, L R Muenz 1, B Bunow 1, D L Birx 1, M L Robb 1
PMCID: PMC192059  PMID: 9311792

Abstract

Three antibody reagents that neutralize primary human immunodeficiency virus type 1 (HIV-1) isolates were tested for magnitude and breadth of neutralization when used alone or in double or triple combinations. Hyperimmune anti-HIV immunoglobulin (HIVIG) is derived from the plasma of HIV-1-infected donors, and monoclonal antibodies (MAbs) 2F5 and 2G12 bind to distinct regions of the HIV-1 envelope glycoprotein. The antibodies were initially tested against a panel of 15 clade B HIV-1 isolates, using a single concentration that is achievable in vivo (HIVIG, 2,500 microg/ml; MAbs, 25 microg/ml). Individual antibody reagents neutralized many of the viruses tested, but antibody potency varied substantially among the viruses. The virus neutralization produced by double combinations of HIVIG plus 2F5 or 2G12, the two MAbs together, or the triple combination of HIVIG, 2F5, and 2G12 was generally equal to or greater than that predicted by the effect of individual antibodies. Overall, the triple combination displayed the greatest magnitude and breadth of neutralization. Synergistic neutralization was evaluated by analyzing data from dose-response curves of each individual antibody reagent compared to the triple combination and was demonstrated against each of four viruses tested. Therefore, combinations of polyclonal and monoclonal anti-HIV antibodies can produce additive or synergistic neutralization of primary HIV-1 isolates. Passive immunotherapy for treatment or prophylaxis of HIV-1 should consider mixtures of potent neutralizing antibody reagents to expand the magnitude and breadth of virus neutralization.

Full Text

The Full Text of this article is available as a PDF (223.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allaway G. P., Ryder A. M., Beaudry G. A., Maddon P. J. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res Hum Retroviruses. 1993 Jul;9(7):581–587. doi: 10.1089/aid.1993.9.581. [DOI] [PubMed] [Google Scholar]
  2. Ashorn P., Moss B., Weinstein J. N., Chaudhary V. K., FitzGerald D. J., Pastan I., Berger E. A. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8889–8893. doi: 10.1073/pnas.87.22.8889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bahmanyar M., Fayaz A., Nour-Salehi S., Mohammadi M., Koprowski H. Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA. 1976 Dec 13;236(24):2751–2754. [PubMed] [Google Scholar]
  4. Beasley R. P., Hwang L. Y., Stevens C. E., Lin C. C., Hsieh F. J., Wang K. Y., Sun T. S., Szmuness W. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983 Mar-Apr;3(2):135–141. doi: 10.1002/hep.1840030201. [DOI] [PubMed] [Google Scholar]
  5. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., Gruber G., Tauer C., Steindl F., Jungbauer A. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses. 1994 Apr;10(4):359–369. doi: 10.1089/aid.1994.10.359. [DOI] [PubMed] [Google Scholar]
  6. Buchbinder A., Karwowska S., Gorny M. K., Burda S. T., Zolla-Pazner S. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses. 1992 Apr;8(4):425–427. doi: 10.1089/aid.1992.8.425. [DOI] [PubMed] [Google Scholar]
  7. Burkly L., Mulrey N., Blumenthal R., Dimitrov D. S. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J Virol. 1995 Jul;69(7):4267–4273. doi: 10.1128/jvi.69.7.4267-4273.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Burton D. R., Pyati J., Koduri R., Sharp S. J., Thornton G. B., Parren P. W., Sawyer L. S., Hendry R. M., Dunlop N., Nara P. L. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994 Nov 11;266(5187):1024–1027. doi: 10.1126/science.7973652. [DOI] [PubMed] [Google Scholar]
  9. Cao J., Bergeron L., Helseth E., Thali M., Repke H., Sodroski J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol. 1993 May;67(5):2747–2755. doi: 10.1128/jvi.67.5.2747-2755.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cavacini L. A., Power J., Emes C. L., Mace K., Treacy G., Posner M. R. Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys. J Immunother Emphasis Tumor Immunol. 1994 May;15(4):251–256. doi: 10.1097/00002371-199405000-00003. [DOI] [PubMed] [Google Scholar]
  11. Chou T. C., Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem. 1977 Sep 25;252(18):6438–6442. [PubMed] [Google Scholar]
  12. Conley A. J., Gorny M. K., Kessler J. A., 2nd, Boots L. J., Ossorio-Castro M., Koenig S., Lineberger D. W., Emini E. A., Williams C., Zolla-Pazner S. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol. 1994 Nov;68(11):6994–7000. doi: 10.1128/jvi.68.11.6994-7000.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Conley A. J., Kessler J. A., 2nd, Boots L. J., McKenna P. M., Schleif W. A., Emini E. A., Mark G. E., 3rd, Katinger H., Cobb E. K., Lunceford S. M. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol. 1996 Oct;70(10):6751–6758. doi: 10.1128/jvi.70.10.6751-6758.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Conley A. J., Kessler J. A., 2nd, Boots L. J., Tung J. S., Arnold B. A., Keller P. M., Shaw A. R., Emini E. A. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3348–3352. doi: 10.1073/pnas.91.8.3348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cummins L. M., Weinhold K. J., Matthews T. J., Langlois A. J., Perno C. F., Condie R. M., Allain J. P. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood. 1991 Mar 1;77(5):1111–1117. [PubMed] [Google Scholar]
  16. D'Souza M. P., Milman G., Bradac J. A., McPhee D., Hanson C. V., Hendry R. M. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS. 1995 Aug;9(8):867–874. doi: 10.1097/00002030-199508000-00006. [DOI] [PubMed] [Google Scholar]
  17. Davis D., Stephens D. M., Carne C. A., Lachmann P. J. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope. J Gen Virol. 1993 Dec;74(Pt 12):2609–2617. doi: 10.1099/0022-1317-74-12-2609. [DOI] [PubMed] [Google Scholar]
  18. Delwart E. L., Shpaer E. G., Louwagie J., McCutchan F. E., Grez M., Rübsamen-Waigmann H., Mullins J. I. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science. 1993 Nov 19;262(5137):1257–1261. doi: 10.1126/science.8235655. [DOI] [PubMed] [Google Scholar]
  19. Eichberg J. W., Murthy K. K., Ward R. H., Prince A. M. Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1515–1515. doi: 10.1089/aid.1992.8.1515. [DOI] [PubMed] [Google Scholar]
  20. Emanuel D., Cunningham I., Jules-Elysee K., Brochstein J. A., Kernan N. A., Laver J., Stover D., White D. A., Fels A., Polsky B. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988 Nov 15;109(10):777–782. doi: 10.7326/0003-4819-109-10-777. [DOI] [PubMed] [Google Scholar]
  21. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992 Feb 20;355(6362):728–730. doi: 10.1038/355728a0. [DOI] [PubMed] [Google Scholar]
  22. Frickhofen N., Abkowitz J. L., Safford M., Berry J. M., Antunez-de-Mayolo J., Astrow A., Cohen R., Halperin I., King L., Mintzer D. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990 Dec 15;113(12):926–933. doi: 10.7326/0003-4819-113-12-926. [DOI] [PubMed] [Google Scholar]
  23. Gao F., Yue L., Craig S., Thornton C. L., Robertson D. L., McCutchan F. E., Bradac J. A., Sharp P. M., Hahn B. H. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses. 1994 Nov;10(11):1359–1368. doi: 10.1089/aid.1994.10.1359. [DOI] [PubMed] [Google Scholar]
  24. Gorny M. K., Moore J. P., Conley A. J., Karwowska S., Sodroski J., Williams C., Burda S., Boots L. J., Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol. 1994 Dec;68(12):8312–8320. doi: 10.1128/jvi.68.12.8312-8320.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Groothuis J. R., Simoes E. A., Levin M. J., Hall C. B., Long C. E., Rodriguez W. J., Arrobio J., Meissner H. C., Fulton D. R., Welliver R. C. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 1993 Nov 18;329(21):1524–1530. doi: 10.1056/NEJM199311183292102. [DOI] [PubMed] [Google Scholar]
  26. Günthard H. F., Gowland P. L., Schüpbach J., Fung M. S., Böni J., Liou R. S., Chang N. T., Grob P., Graepel P., Braun D. G. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J Infect Dis. 1994 Dec;170(6):1384–1393. doi: 10.1093/infdis/170.6.1384. [DOI] [PubMed] [Google Scholar]
  27. HAMMON W. M., CORIELL L. L., WEHRLE P. F., STOKES J., Jr Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. J Am Med Assoc. 1953 Apr 11;151(15):1272–1285. [PubMed] [Google Scholar]
  28. Hinkula J., Bratt G., Gilljam G., Nordlund S., Broliden P. A., Holmberg V., Olausson-Hansson E., Albert J., Sandström E., Wahren B. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. J Acquir Immune Defic Syndr. 1994 Sep;7(9):940–951. [PubMed] [Google Scholar]
  29. Jackson G. G., Perkins J. T., Rubenis M., Paul D. A., Knigge M., Despotes J. C., Spencer P. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet. 1988 Sep 17;2(8612):647–652. doi: 10.1016/s0140-6736(88)90468-0. [DOI] [PubMed] [Google Scholar]
  30. Jacobson J. M., Colman N., Ostrow N. A., Simson R. W., Tomesch D., Marlin L., Rao M., Mills J. L., Clemens J., Prince A. M. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis. 1993 Aug;168(2):298–305. doi: 10.1093/infdis/168.2.298. [DOI] [PubMed] [Google Scholar]
  31. Japour A. J., Fiscus S. A., Arduino J. M., Mayers D. L., Reichelderfer P. S., Kuritzkes D. R. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol. 1994 Sep;32(9):2291–2294. doi: 10.1128/jcm.32.9.2291-2294.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. KORNS R. F. Prophylaxis of German measles with immune serum globulin. J Infect Dis. 1952 Mar-Apr;90(2):183–189. doi: 10.1093/infdis/90.2.183. [DOI] [PubMed] [Google Scholar]
  33. KRUGMAN S. The clinical use of gamma globulin. N Engl J Med. 1963 Jul 25;269:195–201. doi: 10.1056/NEJM196307252690406. [DOI] [PubMed] [Google Scholar]
  34. Kalyanaraman V. S., Rodriguez V., Veronese F., Rahman R., Lusso P., DeVico A. L., Copeland T., Oroszlan S., Gallo R. C., Sarngadharan M. G. Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1990 Mar;6(3):371–380. doi: 10.1089/aid.1990.6.371. [DOI] [PubMed] [Google Scholar]
  35. Karpas A., Hill F., Youle M., Cullen V., Gray J., Byron N., Hayhoe F., Tenant-Flowers M., Howard L., Gilgen D. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9234–9237. doi: 10.1073/pnas.85.23.9234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Kennedy M. S., Orloff S., Ibegbu C. C., Odell C. D., Maddon P. J., McDougal J. S. Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity. AIDS Res Hum Retroviruses. 1991 Dec;7(12):975–981. doi: 10.1089/aid.1991.7.975. [DOI] [PubMed] [Google Scholar]
  37. Laal S., Burda S., Gorny M. K., Karwowska S., Buchbinder A., Zolla-Pazner S. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol. 1994 Jun;68(6):4001–4008. doi: 10.1128/jvi.68.6.4001-4008.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Lambert J. S., Mofenson L. M., Fletcher C. V., Moye J., Jr, Stiehm E. R., Meyer W. A., 3rd, Nemo G. J., Mathieson B. J., Hirsch G., Sapan C. V. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis. 1997 Feb;175(2):283–291. doi: 10.1093/infdis/175.2.283. [DOI] [PubMed] [Google Scholar]
  39. Levy J., Youvan T., Lee M. L. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The Passive Hyperimmune Therapy Study Group. Blood. 1994 Oct 1;84(7):2130–2135. [PubMed] [Google Scholar]
  40. Louwagie J., Janssens W., Mascola J., Heyndrickx L., Hegerich P., van der Groen G., McCutchan F. E., Burke D. S. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol. 1995 Jan;69(1):263–271. doi: 10.1128/jvi.69.1.263-271.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Mascola J. R., Burke D. S. Antigen detection in neutralization assays: high levels of interfering anti-p24 antibodies in some plasma. AIDS Res Hum Retroviruses. 1993 Dec;9(12):1173–1174. doi: 10.1089/aid.1993.9.1173. [DOI] [PubMed] [Google Scholar]
  42. Mascola J. R., Louwagie J., McCutchan F. E., Fischer C. L., Hegerich P. A., Wagner K. F., Fowler A. K., McNeil J. G., Burke D. S. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis. 1994 Jan;169(1):48–54. doi: 10.1093/infdis/169.1.48. [DOI] [PubMed] [Google Scholar]
  43. Mascola J. R., Snyder S. W., Weislow O. S., Belay S. M., Belshe R. B., Schwartz D. H., Clements M. L., Dolin R., Graham B. S., Gorse G. J. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996 Feb;173(2):340–348. doi: 10.1093/infdis/173.2.340. [DOI] [PubMed] [Google Scholar]
  44. McKeating J. A., Cordell J., Dean C. J., Balfe P. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology. 1992 Dec;191(2):732–742. doi: 10.1016/0042-6822(92)90249-o. [DOI] [PubMed] [Google Scholar]
  45. Montefiori D. C., Graham B. S., Zhou J., Zhou J., Bucco R. A., Schwartz D. H., Cavacini L. A., Posner M. R. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. J Clin Invest. 1993 Aug;92(2):840–847. doi: 10.1172/JCI116658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993 Nov;67(11):6642–6647. doi: 10.1128/jvi.67.11.6642-6647.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Neurath A. R., Strick N., Lin K., Jiang S. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. AIDS Res Hum Retroviruses. 1995 Jun;11(6):687–696. doi: 10.1089/aid.1995.11.687. [DOI] [PubMed] [Google Scholar]
  48. Osther K., Wiik A., Black F., Skinhøj P., Kellermann G., Ugen K. E., Williams W. V., Weiner D. B. PASSHIV-1 treatment of patients with HIV-1 infection. A preliminary report of a phase I trial of hyperimmune porcine immunoglobulin to HIV-1. AIDS. 1992 Dec;6(12):1457–1464. doi: 10.1097/00002030-199212000-00006. [DOI] [PubMed] [Google Scholar]
  49. Potts B. J., Field K. G., Wu Y., Posner M., Cavacini L., White-Scharf M. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. Virology. 1993 Nov;197(1):415–419. doi: 10.1006/viro.1993.1604. [DOI] [PubMed] [Google Scholar]
  50. Prince A. M., Reesink H., Pascual D., Horowitz B., Hewlett I., Murthy K. K., Cobb K. E., Eichberg J. W. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses. 1991 Dec;7(12):971–973. doi: 10.1089/aid.1991.7.971. [DOI] [PubMed] [Google Scholar]
  51. ROSS A. H. Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med. 1962 Aug 23;267:369–376. doi: 10.1056/NEJM196208232670801. [DOI] [PubMed] [Google Scholar]
  52. Sattentau Q. J., Zolla-Pazner S., Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology. 1995 Jan 10;206(1):713–717. doi: 10.1016/s0042-6822(95)80094-8. [DOI] [PubMed] [Google Scholar]
  53. Snydman D. R., Werner B. G., Heinze-Lacey B., Berardi V. P., Tilney N. L., Kirkman R. L., Milford E. L., Cho S. I., Bush H. L., Jr, Levey A. S. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987 Oct 22;317(17):1049–1054. doi: 10.1056/NEJM198710223171703. [DOI] [PubMed] [Google Scholar]
  54. Stiehm E. R., Mofenson L., Zolla-Pazner S., Jackson B., Martin N. L., Ammann A. J. Summary of the workshop on passive immunotherapy in the prevention and treatment of HIV infection. The Passive Antibody Workshop Participants. Clin Immunol Immunopathol. 1995 Apr;75(1):84–93. doi: 10.1006/clin.1995.1056. [DOI] [PubMed] [Google Scholar]
  55. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Alter H. J., Taylor P. E., DeVera A., Chen G. T., Kellner A. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med. 1982 Dec 9;307(24):1481–1486. doi: 10.1056/NEJM198212093072403. [DOI] [PubMed] [Google Scholar]
  56. Thali M., Furman C., Wahren B., Posner M., Ho D. D., Robinson J., Sodroski J. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr. 1992;5(6):591–599. [PubMed] [Google Scholar]
  57. Tilley S. A., Honnen W. J., Racho M. E., Chou T. C., Pinter A. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res Hum Retroviruses. 1992 Apr;8(4):461–467. doi: 10.1089/aid.1992.8.461. [DOI] [PubMed] [Google Scholar]
  58. Trkola A., Dragic T., Arthos J., Binley J. M., Olson W. C., Allaway G. P., Cheng-Mayer C., Robinson J., Maddon P. J., Moore J. P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996 Nov 14;384(6605):184–187. doi: 10.1038/384184a0. [DOI] [PubMed] [Google Scholar]
  59. Trkola A., Pomales A. B., Yuan H., Korber B., Maddon P. J., Allaway G. P., Katinger H., Barbas C. F., 3rd, Burton D. R., Ho D. D. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 1995 Nov;69(11):6609–6617. doi: 10.1128/jvi.69.11.6609-6617.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J. P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996 Feb;70(2):1100–1108. doi: 10.1128/jvi.70.2.1100-1108.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. VanCott T. C., Bethke F. R., Burke D. S., Redfield R. R., Birx D. L. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol. 1995 Oct 15;155(8):4100–4110. [PubMed] [Google Scholar]
  62. VanCott T. C., Bethke F. R., Polonis V. R., Gorny M. K., Zolla-Pazner S., Redfield R. R., Birx D. L. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol. 1994 Jul 1;153(1):449–459. [PubMed] [Google Scholar]
  63. VanCott T. C., Loomis L. D., Redfield R. R., Birx D. L. Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. J Immunol Methods. 1992 Feb 5;146(2):163–176. doi: 10.1016/0022-1759(92)90225-i. [DOI] [PubMed] [Google Scholar]
  64. VanCott T. C., Veit S. C., Kalyanaraman V., Earl P., Birx D. L. Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen. J Immunol Methods. 1995 Jun 14;183(1):103–117. doi: 10.1016/0022-1759(95)00038-c. [DOI] [PubMed] [Google Scholar]
  65. Vijh-Warrier S., Pinter A., Honnen W. J., Tilley S. A. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J Virol. 1996 Jul;70(7):4466–4473. doi: 10.1128/jvi.70.7.4466-4473.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Vittecoq D., Mattlinger B., Barre-Sinoussi F., Courouce A. M., Rouzioux C., Doinel C., Bary M., Viard J. P., Bach J. F., Rouger P. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis. 1992 Feb;165(2):364–368. doi: 10.1093/infdis/165.2.364. [DOI] [PubMed] [Google Scholar]
  67. Weinstein J. N., Bunow B., Weislow O. S., Schinazi R. F., Wahl S. M., Wahl L. M., Szebeni J. Synergistic drug combinations in AIDS therapy. Dipyridamole/3'-azido-3'-deoxythymidine in particular and principles of analysis in general. Ann N Y Acad Sci. 1990;616:367–384. doi: 10.1111/j.1749-6632.1990.tb17857.x. [DOI] [PubMed] [Google Scholar]
  68. Wolfe E. J., Cavacini L. A., Samore M. H., Posner M. R., Kozial C., Spino C., Trapnell C. B., Ketter N., Hammer S., Gambertoglio J. G. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Clin Pharmacol Ther. 1996 Jun;59(6):662–667. doi: 10.1016/S0009-9236(96)90006-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES